Physician profile
Steven J Class
NPI 1841292380
$3,765.18
in general payments reported to CMS, 2019-2025
33 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $257 · 2021: $470 · 2022: $513 · 2023: $868 · 2024: $607 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,052.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,051.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $746.22 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $471.93 | 2019-2025 | Lifevest |
| Pfizer INC. | $467.71 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $256.80 | 2021-2024 | Verquvo |
| Amgen INC. | $246.84 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $142.87 | 2023 | Optimizer |
| Abbott Laboratories | $131.26 | 2021-2024 | Aveir |
| E.R. Squibb & Sons, L.L.C. | $119.91 | 2020-2025 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $119.23 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $99.76 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $88.17 | 2022-2023 | Assure Wcd |
| Astrazeneca Pharmaceuticals LP | $78.86 | 2019-2023 | Farxiga, Andexxa |
| Janssen Pharmaceuticals, INC | $77.95 | 2021-2022 | |
| Amarin Pharma, INC. | $70.70 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.15 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $65.11 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Cvrx, INC. | $65.07 | 2022-2024 | Barostim Neo System |
| Boston Scientific Corporation | $59.55 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $54.05 | 2021-2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $43.64 | 2024 | Amvuttra, Onpattro |
| Acutus Medical, INC. | $40.07 | 2022 | |
| Novo Nordisk INC | $35.55 | 2023-2024 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $33.59 | 2019-2024 | Evkeeza |
| Philips North America LLC | $27.50 | 2025 | Diagnostic Ecg Service |
| Heartflow, INC. | $26.10 | 2025 | |
| Penumbra, INC. | $23.00 | 2021-2022 | |
| Astellas Pharma US INC | $22.93 | 2023 | Veozah |
| Biosense Webster, INC. | $19.70 | 2025 | Nuvision Ice Catheter |
| Abiomed | $16.60 | 2023 | Impella |
| Esperion Therapeutics, INC. | $16.47 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $15.53 | 2023 | Inpefa |
| Sobi, INC | $13.98 | 2021 | |
| Cardiovascular Systems INC. | $1.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Class listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.